Cases & Deals

Share

Astellas Pharma acquires iota Biosciences

October 2020

Client(s) Astellas Pharma Inc.

Jones Day advised Astellas Pharma Inc. in its acquisition of iota Biosciences. Under the Merger Agreement, Astellas made an initial payment of approximately $127.5 million to acquire all of the outstanding equity in iota not already held by Astellas (Astellas through a U.S. subsidiary, is already an investor in iota through its previous Series A Preferred Stock offering). iota’s shareholders (other than Astellas) will be eligible to receive additional payments of up to a total of approximately $176.5 million upon achievement of predetermined milestones by iota within certain timeframes after completion of the transaction.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.